Bactiguard’s Q2 net sales of SEK 54m came in +11% vs SEB (SEK 49m). Wound management revenues were +29% vs SEBe, explaining the difference as license reveunes are in line. However, the BD revenues are better than SEBe and there were no Well Lead sales in Q2. Q2 supports Bactiguard’s Q1 comment of the BD weakness being temporary. Q2 EBITDA comes only marginally below SEBe indicating somewhat higher costs. All in all, no drama, we say, and good to see BD revenues normalising.
LÄS MER
